

Peter E Lipsky

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6839287/publications.pdf>

Version: 2024-02-01

156
papers

19,864
citations

18436

62
h-index

10708

138
g-index

164
all docs

164
docs citations

164
times ranked

17463
citing authors

#	ARTICLE	IF	CITATIONS
1	Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2000, 343, 1594-1602.	13.9	2,910
2	Cyclooxygenase in biology and disease. <i>FASEB Journal</i> , 1998, 12, 1063-1073.	0.2	2,208
3	Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. <i>Nature Immunology</i> , 2001, 2, 764-766.	7.0	637
4	Regulation of B Cell Differentiation and Plasma Cell Generation by IL-21, a Novel Inducer of Blimp-1 and Bcl-6. <i>Journal of Immunology</i> , 2004, 173, 5361-5371.	0.4	588
5	IL-21 Induces Differentiation of Human Naive and Memory B Cells into Antibody-Secreting Plasma Cells. <i>Journal of Immunology</i> , 2005, 175, 7867-7879.	0.4	580
6	Disturbed Peripheral B Lymphocyte Homeostasis in Systemic Lupus Erythematosus. <i>Journal of Immunology</i> , 2000, 165, 5970-5979.	0.4	564
7	Identification and characterization of circulating human transitional B cells. <i>Blood</i> , 2005, 105, 4390-4398.	0.6	504
8	Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. <i>Arthritis and Rheumatism</i> , 2010, 62, 542-552.	6.7	469
9	Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: Efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. <i>Arthritis and Rheumatism</i> , 1998, 41, 1591-1602.	6.7	457
10	Efficacy and Tolerability of Pegloticase for the Treatment of Chronic Gout in Patients Refractory to Conventional Treatment. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 711.	3.8	433
11	Medicinal chemistry and pharmacology of genus <i>Tripterygium</i> (Celastraceae). <i>Phytochemistry</i> , 2007, 68, 732-766.	1.4	367
12	Correlation between circulating CD27 ^{high} plasma cells and disease activity in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2003, 48, 1332-1342.	6.7	319
13	Essential Role of IL-21 in B Cell Activation, Expansion, and Plasma Cell Generation during CD4 ⁺ T Cell-B Cell Collaboration. <i>Journal of Immunology</i> , 2007, 179, 5886-5896.	0.4	284
14	Benefit of an extract of <i>Tripterygium Wilfordii</i> Hook F in patients with rheumatoid arthritis: A double-blind, placebo-controlled study. <i>Arthritis and Rheumatism</i> , 2002, 46, 1735-1743.	6.7	279
15	Basic biology and clinical application of specific cyclooxygenase-2 inhibitors. <i>Arthritis and Rheumatism</i> , 2000, 43, 4-13.	6.7	273
16	Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. <i>Arthritis and Rheumatism</i> , 1994, 37, 992-999.	6.7	268
17	Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: Delineation by expression of CD27, IgD, and CD95. <i>Arthritis and Rheumatism</i> , 2008, 58, 1762-1773.	6.7	263
18	THE CHINESE ANTI-INFLAMMATORY AND IMMUNOSUPPRESSIVE HERBAL REMEDY <i>TRIPTERYGIUM WILFORDII</i> HOOK F. <i>Rheumatic Disease Clinics of North America</i> , 2000, 26, 29-50.	0.8	261

#	ARTICLE	IF	CITATIONS
19	Lymphoid Chemokine B Cell-Attracting Chemokine-1 (CXCL13) Is Expressed in Germinal Center of Ectopic Lymphoid Follicles Within the Synovium of Chronic Arthritis Patients. <i>Journal of Immunology</i> , 2001, 166, 650-655.	0.4	254
20	Phenotypic analysis of synovial tissue and peripheral blood lymphocytes isolated from patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1988, 31, 1230-1238.	6.7	246
21	Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. <i>Lancet</i> , The, 2018, 392, 1330-1339.	6.3	244
22	Mechanisms of B cell autoimmunity in SLE. <i>Arthritis Research and Therapy</i> , 2011, 13, 243.	1.6	225
23	Elevated interleukin-10 levels in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1995, 38, 96-104.	6.7	209
24	Comparison of <i>Tripterygium wilfordii</i> Hook F Versus Sulfasalazine in the Treatment of Rheumatoid Arthritis. <i>Annals of Internal Medicine</i> , 2009, 151, 229.	2.0	196
25	Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout. <i>Arthritis Research and Therapy</i> , 2014, 16, R60.	1.6	195
26	Comparison of <i>Tripterygium wilfordii</i> Hook F with methotrexate in the treatment of active rheumatoid arthritis (TRIFRA): a randomised, controlled clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1078-1086.	0.5	189
27	Clinical characteristics of immunoglobulin G4-related disease: a prospective study of 118 Chinese patients. <i>Rheumatology</i> , 2015, 54, 1982-1990.	0.9	185
28	Glutathione peroxidase 4-regulated neutrophil ferroptosis induces systemic autoimmunity. <i>Nature Immunology</i> , 2021, 22, 1107-1117.	7.0	185
29	Accessory Cell Signals Involved in T-Cell Activation. <i>Immunological Reviews</i> , 1990, 117, 5-66.	2.8	170
30	SLE Peripheral Blood B Cell, T Cell and Myeloid Cell Transcriptomes Display Unique Profiles and Each Subset Contributes to the Interferon Signature. <i>PLoS ONE</i> , 2013, 8, e67003.	1.1	165
31	Defective PTEN regulation contributes to B cell hyperresponsiveness in systemic lupus erythematosus. <i>Science Translational Medicine</i> , 2014, 6, 246ra99.	5.8	145
32	New insights into the role of antinuclear antibodies in systemic lupus erythematosus. <i>Nature Reviews Rheumatology</i> , 2020, 16, 565-579.	3.5	145
33	IL-21 and BAFF/BLyS Synergize in Stimulating Plasma Cell Differentiation from a Unique Population of Human Splenic Memory B Cells. <i>Journal of Immunology</i> , 2007, 178, 2872-2882.	0.4	143
34	Anti-inflammatory and immunosuppressive compounds from <i>Tripterygium wilfordii</i> . <i>Phytochemistry</i> , 2007, 68, 1172-1178.	1.4	135
35	How to report radiographic data in randomized clinical trials in rheumatoid arthritis: Guidelines from a roundtable discussion. <i>Arthritis and Rheumatism</i> , 2002, 47, 215-218.	6.7	132
36	B cells in autoimmunity. <i>Arthritis Research and Therapy</i> , 2009, 11, 247.	1.6	130

#	ARTICLE	IF	CITATIONS
37	Identification and Characterization of a Human CD5+ Pre-Naive B Cell Population. Journal of Immunology, 2009, 182, 4116-4126.	0.4	127
38	Inhibition of Human Helper T Cell Function In Vitro by d-Penicillamine and CuSO4. Journal of Clinical Investigation, 1980, 65, 1069-1076.	3.9	124
39	Characterization of the Human Ig Heavy Chain Antigen Binding Complementarity Determining Region 3 Using a Newly Developed Software Algorithm, JOINSOLVER. Journal of Immunology, 2004, 172, 6790-6802.	0.4	120
40	Spontaneous and induced membrane hyperpolarizations in macrophages. Journal of Cellular Physiology, 1975, 86, 653-661.	2.0	118
41	Effect of an Extract of the Chinese Herbal Remedy Tripterygium Wilfordii Hook F on Human Immune Responsiveness. Arthritis and Rheumatism, 1991, 34, 1274-1281.	6.7	117
42	Somatic hypermutation of human immunoglobulin heavy chain genes: targeting of RGYW motifs on both DNA strands. European Journal of Immunology, 1998, 28, 3384-3396.	1.6	117
43	Comprehensive transcriptomic analysis of COVID-19 blood, lung, and airway. Scientific Reports, 2021, 11, 7052.	1.6	113
44	Abnormalities of B cell subsets in patients with systemic lupus erythematosus. Journal of Immunological Methods, 2011, 363, 187-197.	0.6	111
45	Circulating plasmablasts/plasma cells: a potential biomarker for IgG4-related disease. Arthritis Research and Therapy, 2017, 19, 25.	1.6	110
46	Effects of tripterygium wilfordii Hook F extracts on induction of cyclooxygenase 2 activity and prostaglandin E2 production. Arthritis and Rheumatism, 1998, 41, 130-138.	6.7	109
47	A polymorphism within <i>IL21R</i> confers risk for systemic lupus erythematosus. Arthritis and Rheumatism, 2009, 60, 2402-2407.	6.7	108
48	The roles of interleukin 2 and interferon- β in human B cell activation, growth and differentiation. European Journal of Immunology, 1986, 16, 925-932.	1.6	104
49	Presentation of self peptides by dendritic cells. Possible implications for the pathogenesis of rheumatoid arthritis. Arthritis and Rheumatism, 1996, 39, 183-190.	6.7	100
50	Assay variation in the detection of antinuclear antibodies in the sera of patients with established SLE. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2017-212599.	0.5	98
51	Increased levels of circulating intercellular adhesion molecule 1 in the sera of patients with rheumatoid arthritis. Arthritis and Rheumatism, 1993, 36, 1098-1102.	6.7	95
52	Repeat treatment of Rheumatoid Arthritis patients with a murine anti-intercellular adhesion molecule 1 monoclonal antibody. Arthritis and Rheumatism, 1997, 40, 849-853.	6.7	95
53	Rheumatoid synovium is enriched in CD45RBdim mature memory T cells that are potent helpers for B cell differentiation. Arthritis and Rheumatism, 1992, 35, 1455-1465.	6.7	94
54	Aberrant Expansion and Function of Follicular Helper T Cell Subsets in IgG4-Related Disease. Arthritis and Rheumatology, 2018, 70, 1853-1865.	2.9	89

#	ARTICLE	IF	CITATIONS
55	The pathogenesis of systemic lupus erythematosus: Harnessing big data to understand the molecular basis of lupus. <i>Journal of Autoimmunity</i> , 2020, 110, 102359.	3.0	89
56	IgG and IgM rheumatoid factor synthesis in rheumatoid synovial membrane cell cultures. <i>Arthritis and Rheumatism</i> , 1985, 28, 742-752.	6.7	86
57	Effects of administration of an anti-cd5 plus immunoconjugate in rheumatoid arthritis. results of two phase ii studies. <i>Arthritis and Rheumatism</i> , 1993, 36, 620-630.	6.7	86
58	Identification of alterations in macrophage activation associated with disease activity in systemic lupus erythematosus. <i>PLoS ONE</i> , 2018, 13, e0208132.	1.1	80
59	TRAF3 Forms Heterotrimers with TRAF2 and Modulates Its Ability to Mediate NF- κ B Activation. <i>Journal of Biological Chemistry</i> , 2004, 279, 55855-55865.	1.6	76
60	Single-cell sequencing of immune cells from anticitrullinated peptide antibody positive and negative rheumatoid arthritis. <i>Nature Communications</i> , 2021, 12, 4977.	5.8	73
61	Beyond pan-B-cell-directed therapy " new avenues and insights into the pathogenesis of SLE. <i>Nature Reviews Rheumatology</i> , 2016, 12, 645-657.	3.5	69
62	Drug repurposing to improve treatment of rheumatic autoimmune inflammatory diseases. <i>Nature Reviews Rheumatology</i> , 2020, 16, 32-52.	3.5	68
63	Gene expression analysis delineates the potential roles of multiple interferons in systemic lupus erythematosus. <i>Communications Biology</i> , 2019, 2, 140.	2.0	66
64	The intrinsic migratory capacity of memory T cells contributes to their accumulation in rheumatoid synovium. <i>Arthritis and Rheumatism</i> , 1992, 35, 1434-1444.	6.7	64
65	New concepts in the pathogenesis of Sjögren syndrome: many questions, fewer answers. <i>Current Opinion in Rheumatology</i> , 2003, 15, 563-570.	2.0	64
66	Correlation of serologic indicators of inflammation with effectiveness of nonsteroidal antiinflammatory drug therapy in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1990, 33, 19-28.	6.7	61
67	The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2015, 14, 1079-1086.	2.5	59
68	Increased Frequency of a Unique Spleen Tyrosine Kinase Bright Memory B Cell Population in Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2014, 66, 3424-3435.	2.9	58
69	Machine learning approaches to predict lupus disease activity from gene expression data. <i>Scientific Reports</i> , 2019, 9, 9617.	1.6	58
70	Dendritic Cells: Origin and Differentiation. <i>Stem Cells</i> , 1996, 14, 196-206.	1.4	56
71	A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1996, 39, 1102-1108.	6.7	55
72	A flow cytometric method to detect protein-protein interaction in living cells by directly visualizing donor fluorophore quenching during CFP-YFP fluorescence resonance energy transfer (FRET). <i>Cytometry</i> , 2003, 55A, 71-85.	1.8	54

#	ARTICLE	IF	CITATIONS
73	Molecular Characterization of Circulating Plasma Cells in Patients with Active Systemic Lupus Erythematosus. PLoS ONE, 2012, 7, e44362.	1.1	54
74	Somatic hypermutation of V λ J λ rearrangements: targeting of RGYW motifs on both DNA strands and preferential selection of mutated codons within RGYW motifs. European Journal of Immunology, 1999, 29, 4011-4021.	1.6	48
75	Determination of tumor necrosis factor receptor-associated factor trimerization in living cells by CFP->YFP->mRFP FRET detected by flow cytometry. Nucleic Acids Research, 2005, 33, e61-e61.	6.5	48
76	Comparison of the impact of Tripterygium wilfordii Hook F and Methotrexate treatment on radiological progression in active rheumatoid arthritis: 2-year follow-up of a randomized, non-blinded, controlled study. Arthritis Research and Therapy, 2018, 20, 70.	1.6	47
77	Patient ancestry significantly contributes to molecular heterogeneity of systemic lupus erythematosus. JCI Insight, 2020, 5, .	2.3	47
78	TRAF6 Regulates Cell Fate Decisions by Inducing Caspase 8-dependent Apoptosis and the Activation of NF- κ B. Journal of Biological Chemistry, 2006, 281, 11235-11249.	1.6	44
79	Splenic proliferative lymphoid nodules distinct from germinal centers are sites of autoantigen stimulation in immune thrombocytopenia. Blood, 2012, 120, 5021-5031.	0.6	43
80	New Perspectives in Rheumatology: Biomarkers as Entry Criteria for Clinical Trials of New Therapies for Systemic Lupus Erythematosus: The Example of Antinuclear Antibodies and Anti- α -DNA. Arthritis and Rheumatology, 2017, 69, 487-493.	2.9	42
81	Identification and Characterization of Post-activated B Cells in Systemic Autoimmune Diseases. Frontiers in Immunology, 2019, 10, 2136.	2.2	41
82	The control of antibody production by immunomodulatory molecules. Arthritis and Rheumatism, 1989, 32, 1345-1355.	6.7	40
83	Flow cytometric assessment of the signaling status of human B lymphocytes from normal and autoimmune individuals. Arthritis Research, 2004, 6, 28.	2.0	40
84	B cells. Current Opinion in Rheumatology, 2014, 26, 228-236.	2.0	40
85	Sjögren's syndrome presenting as hypokalemic periodic paralysis. Arthritis and Rheumatism, 1993, 36, 1735-1738.	6.7	39
86	Elevated cytokine messenger RNA levels in the peripheral blood of patients with rheumatoid arthritis suggest different degrees of myeloid cell activation. Arthritis and Rheumatism, 1997, 40, 639-647.	6.7	39
87	Current challenges in the development of new treatments for lupus. Annals of the Rheumatic Diseases, 2019, 78, 729-735.	0.5	39
88	Genomic Identification of Low-Density Granulocytes and Analysis of Their Role in the Pathogenesis of Systemic Lupus Erythematosus. Journal of Immunology, 2019, 202, 3309-3317.	0.4	37
89	An introduction to machine learning and analysis of its use in rheumatic diseases. Nature Reviews Rheumatology, 2021, 17, 710-730.	3.5	37
90	Positive impact of an intervention by arthritis patient educators on knowledge and satisfaction of patients in a rheumatology practice. Arthritis and Rheumatism, 1999, 12, 370-375.	6.7	36

#	ARTICLE	IF	CITATIONS
91	Human memory T cell differentiation into Th2-like effector cells is dependent on IL-4 and CD28 stimulation and inhibited by TCR ligation. <i>European Journal of Immunology</i> , 1998, 28, 2517-2529.	1.6	34
92	Comparable impact of mutational and selective influences in shaping the expressed repertoire of peripheral IgM ⁺ /CD5 ⁺ and IgM ⁺ /CD5 ⁺ B cells. <i>European Journal of Immunology</i> , 1998, 28, 657-668.	1.6	33
93	The V λ 1 Repertoire in Human Fetal Spleen: Evidence for Positive Selection and Extensive Receptor Editing. <i>Journal of Immunology</i> , 2000, 165, 6322-6333.	0.4	32
94	Targeting and selection of mutations in human V λ rearrangements. <i>European Journal of Immunology</i> , 2000, 30, 1597-1605.	1.6	31
95	Pegloticase Treatment Significantly Decreases Blood Pressure in Patients With Chronic Gout. <i>Hypertension</i> , 2019, 74, 95-101.	1.3	31
96	Staphylococcal Protein A Deletes B-1a and Marginal Zone B Lymphocytes Expressing Human Immunoglobulins: An Immune Evasion Mechanism. <i>Journal of Immunology</i> , 2005, 175, 7719-7727.	0.4	30
97	Selective Histone Deacetylase 6 Inhibition Normalizes B Cell Activation and Germinal Center Formation in a Model of Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , 2019, 10, 2512.	2.2	30
98	Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase. <i>Arthritis Research and Therapy</i> , 2018, 20, 286.	1.6	28
99	Targeting and subsequent selection of somatic hypermutations in the human V λ repertoire. <i>European Journal of Immunology</i> , 1999, 29, 3122-3132.	1.6	27
100	Antagonizing miR-7 suppresses B cell hyperresponsiveness and inhibits lupus development. <i>Journal of Autoimmunity</i> , 2020, 109, 102440.	3.0	27
101	Relationship between clinical efficacy and laboratory correlates of inflammatory and immunologic activity in rheumatoid arthritis patients treated with nonsteroidal antiinflammatory drugs. <i>Arthritis and Rheumatism</i> , 1990, 33, 623-633.	6.7	25
102	Positive impact of an intervention by arthritis educators on retention of information, confidence, and examination skills of medical students. <i>Arthritis and Rheumatism</i> , 1998, 11, 32-38.	6.7	25
103	Frequency, distribution and immunologic nature of infusion reactions in subjects receiving pegloticase for chronic refractory gout. <i>Arthritis Research and Therapy</i> , 2017, 19, 191.	1.6	25
104	B Cell Superantigens: Potential Modifiers of the Normal Human BCell Repertoire. <i>International Reviews of Immunology</i> , 1997, 14, 309-324.	1.5	24
105	Similar characteristics of the CDR3 of VH 1-69/DP-10 rearrangements in normal human peripheral blood and chronic lymphocytic leukaemia B cells. <i>British Journal of Haematology</i> , 1998, 102, 516-521.	1.2	24
106	Pegloticase treatment of chronic refractory gout: Update on efficacy and safety. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, S31-S38.	1.6	24
107	Analysis of Trans-Ancestral SLE Risk Loci Identifies Unique Biologic Networks and Drug Targets in African and European Ancestries. <i>American Journal of Human Genetics</i> , 2020, 107, 864-881.	2.6	23
108	Machine Learning in Rheumatic Diseases. <i>Clinical Reviews in Allergy and Immunology</i> , 2021, 60, 96-110.	2.9	22

#	ARTICLE	IF	CITATIONS
109	Altered expression of genes controlling metabolism characterizes the tissue response to immune injury in lupus. <i>Scientific Reports</i> , 2021, 11, 14789.	1.6	22
110	Engagement of class I major histocompatibility complex molecules by cell surface CD8 delivers an activation signal. <i>European Journal of Immunology</i> , 1992, 22, 1379-1383.	1.6	21
111	Analysis of the Stability and Degradation Products of Triptolide. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 52, 3-12.	1.2	21
112	Mechanisms That Shape Human Antibody Repertoire Development in Mice Transgenic for Human Ig H and L Chain Loci. <i>Journal of Immunology</i> , 2017, 198, 3963-3977.	0.4	20
113	Engaging African ancestry participants in SLE clinical trials. <i>Lupus Science and Medicine</i> , 2018, 5, e000297.	1.1	20
114	Deficient interleukin-10 production by neonatal T cells does not explain their ineffectiveness at promoting neonatal B cell differentiation. <i>European Journal of Immunology</i> , 1998, 28, 4248-4256.	1.6	19
115	The NF- κ B Canonical Pathway Is Involved in the Control of the Exonucleolytic Processing of Coding Ends during V(D)J Recombination. <i>Journal of Immunology</i> , 2008, 180, 1040-1049.	0.4	19
116	Regulation of T cell proliferation by anti-CD49d and anti-CD29 monoclonal antibodies. <i>Journal of Leukocyte Biology</i> , 1992, 52, 456-462.	1.5	18
117	Development and Validation of a Novel Evidence-Based Lupus Multivariable Outcome Score for Clinical Trials. <i>Arthritis and Rheumatology</i> , 2018, 70, 1450-1458.	2.9	18
118	Anti-RNP antibodies are associated with the interferon gene signature but not decreased complement levels in SLE. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 632-643.	0.5	17
119	Expression and distribution of CD11a/CD18 and CD54 during human T cell-B cell interactions. <i>Journal of Leukocyte Biology</i> , 1992, 52, 97-103.	1.5	16
120	Autoregulatory function of interleukin-10-producing pre-naïve B cells is defective in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2015, 17, 190.	1.6	16
121	Drug Repositioning Strategies for the Identification of Novel Therapies for Rheumatic Autoimmune Inflammatory Diseases. <i>Rheumatic Disease Clinics of North America</i> , 2017, 43, 467-480.	0.8	16
122	Machine learning reveals distinct gene signature profiles in lesional and nonlesional regions of inflammatory skin diseases. <i>Science Advances</i> , 2022, 8, eabn4776.	4.7	15
123	Expression of Human Endogenous Retroviruses in Systemic Lupus Erythematosus: Multiomic Integration With Gene Expression. <i>Frontiers in Immunology</i> , 2021, 12, 661437.	2.2	14
124	The Impact of Protein Acetylation/Deacetylation on Systemic Lupus Erythematosus. <i>International Journal of Molecular Sciences</i> , 2018, 19, 4007.	1.8	13
125	Biological impact of iberdomide in patients with active systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1136-1142.	0.5	13
126	Functional heterogeneity of human antigen-presenting cells: Presentation of soluble antigen but not self-Ia by monocytes. <i>Journal of Clinical Immunology</i> , 1986, 6, 9-20.	2.0	12

#	ARTICLE	IF	CITATIONS
127	Response to the 2020 American College of Rheumatology Guideline for the Management of Gout: Comment on the Article by FitzGerald et al. <i>Arthritis Care and Research</i> , 2020, 72, 1506-1507.	1.5	12
128	Deconvoluting the heterogeneity of SLE: The contribution of ancestry. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 12-23.	1.5	11
129	Therapeutic implications of the anergic/postactivated status of B cells in systemic lupus erythematosus. <i>RMD Open</i> , 2020, 6, e001258.	1.8	10
130	Management of Gout in the United States: A Claims-Based Analysis. <i>ACR Open Rheumatology</i> , 2020, 2, 180-187.	0.9	10
131	Human CD4+ T cell differentiation and effector function. <i>Immunologic Research</i> , 1999, 19, 25-34.	1.3	9
132	Prostaglandin e2 modulation of rheumatoid factor synthesis. <i>Arthritis and Rheumatism</i> , 1988, 31, 1473-1480.	6.7	8
133	The response of human B lymphocytes to oligodeoxynucleotides. <i>Seminars in Immunopathology</i> , 2000, 22, 63-75.	4.0	8
134	Characterization of patients with chronic refractory gout who do and do not have clinically apparent tophi and their response to pegloticase. <i>Rheumatology</i> , 2019, 58, 1422-1431.	0.9	8
135	Increasing Ancestral Diversity in Systemic Lupus Erythematosus Clinical Studies. <i>Arthritis Care and Research</i> , 2020, , .	1.5	8
136	Regulation of B Cell Function by Lobenzarit, A Novel Disease-Modifying Antirheumatic Drug. <i>Arthritis and Rheumatism</i> , 1992, 35, 168-175.	6.7	7
137	Satisfaction of patients attending an arthritis clinic in a county teaching hospital. <i>Arthritis and Rheumatism</i> , 1997, 10, 169-176.	6.7	7
138	Competition between TRAF2 and TRAF6 Regulates NF- κ B Activation in Human B Lymphocytes. <i>Chinese Medical Sciences Journal</i> , 2010, 25, 1-12.	0.2	7
139	Evaluation of Proposed Criteria for Remission and Evidence-Based Development of Criteria for Complete Response in Patients With Chronic Refractory Gout. <i>ACR Open Rheumatology</i> , 2019, 1, 236-243.	0.9	7
140	Similar T-cell oligoclonality in antimitochondrial antibody-positive and -negative primary biliary cirrhosis. <i>Digestive Diseases and Sciences</i> , 2001, 46, 345-351.	1.1	6
141	Measurement of Human and Murine Interleukin 2 and Interleukin 4. <i>Current Protocols in Immunology</i> , 2000, 37, Unit 6.3.	3.6	5
142	Current Status of the Evaluation and Management of Lupus Patients and Future Prospects. <i>Frontiers in Medicine</i> , 2021, 8, 682544.	1.2	5
143	Th1/Th2 cytokine balance in arthritis: Comment on the article by Miossec and van den Berg. <i>Arthritis and Rheumatism</i> , 1998, 41, 1896-1897.	6.7	4
144	An Activation-Induced Cytidine Deaminase-Independent Mechanism of Secondary VH Gene Rearrangement in Preimmune Human B Cells. <i>Journal of Immunology</i> , 2008, 181, 7825-7834.	0.4	4

#	ARTICLE	IF	CITATIONS
145	Dissociation Between Clinical Benefit and Persistent Urate Lowering in Patients with Chronic Refractory Gout Treated with Pegloticase. <i>Journal of Rheumatology</i> , 2020, 47, 605-612.	1.0	3
146	<scp>Patientâ€Reported</scp> Outcome Information Collected from Lupus Patients Using a Mobile Application: Compliance and Validation. <i>ACR Open Rheumatology</i> , 2022, 4, 99-109.	0.9	3
147	TwHF versus methotrexate in the treatment of rheumatoid arthritis: response to Landewe's comment on the TRIFRA study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, e63-e63.	0.5	2
148	Repositioning Drugs for Systemic Lupus Erythematosus. , 2016, , 567-575.		2
149	Development of a multivariable improvement measure for gout. <i>Arthritis Research and Therapy</i> , 2020, 22, 164.	1.6	2
150	Transcriptomics data: pointing the way to subclassification and personalized medicine in systemic lupus erythematosus. <i>Current Opinion in Rheumatology</i> , 2021, 33, 579-585.	2.0	2
151	Reply to: Diagnostic role of anti-dsDNA antibodies: do not forget autoimmune hepatitis. <i>Nature Reviews Rheumatology</i> , 2021, 17, 245-245.	3.5	1
152	Somatic hypermutation of human immunoglobulin heavy chain genes: targeting of RGYW motifs on both DNA strands. <i>European Journal of Immunology</i> , 1998, 28, 3384-3396.	1.6	1
153	Post-hoc analysis of pegloticase pivotal trials in chronic refractory gout: relationship between fluctuations in plasma urate levels and acute flares. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 1085-1092.	0.4	1
154	Utility of Baseline Transcriptomic Analysis of Rheumatoid Arthritis Synovium as an Indicator for Long-Term Clinical Outcomes. <i>Frontiers in Medicine</i> , 2022, 9, 823244.	1.2	1
155	Repositioning drugs for systemic lupus erythematosus. , 2021, , 641-652.		0
156	Pegloticase causes prolonged improvement in multiple disease parameters in patients with chronic refractory gout who maintain low serum urate levels.. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.4	0